Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2026—Roche’s new Cobas Mass Spec solution will be on display this month at the ADLM meeting, as will Diasorin’s new Liaison Nes, Siemens Healthineers’ Atellica DT 250, and much more. CAP TODAY publisher Bob McGonnagle spoke online in late May with representatives of Roche, Diasorin, Sebia, and Siemens Healthineers about how their instruments will solve some of laboratories’ pressing problems. The conversation follows.
May 2026—Has your blood collection container been validated for the assays you have employed it for? At what point does a verification of a blood collection tube become a validation, and how is a laboratory supposed to know when this threshold has been crossed and what actions to take?
May 2026—Cystatin C has notable advantages over serum creatinine as a biomarker of kidney filtration: fewer nonglomerular filtration rate determinants, more accurate dosing of medications with narrow therapeutic windows for individuals with obesity or low muscle mass, and greater accuracy in determining eligibility for a kidney transplant or for a simultaneous liver-kidney or heart-kidney transplant.
March 2026—For a pathology that is invariably associated with dimming—of memory, of relationships, of personality—Alz-heimer’s disease has been linked to remarkably bright news as of late. Blood-based biomarkers, including two that garnered FDA approval last year, have cracked open the door to earlier diagnoses and therapeutic interventions, as well as the potential to reach more patients.
March 2026—Newer sepsis diagnostics, including monocyte distribution width, Intellisep, and MeMed BV, show promise in clinical studies but have limitations.
November 2025—Two new ADLM documents provide guidance on toxicology testing for emergency departments, replacing a 2003 guideline. The documents address test menus, turnaround times, and the importance of educating ED staff on assay limitations.
November 2025—A 24-year-old female with hereditary stomatocytosis presented with a critical potassium concentration of 7.9 mmol/L. Despite ruling out common causes like hemolysis and EDTA contamination, the elevated potassium persisted, leading to a diagnosis of a PIEZ01 mutation causing potassium leakage.
October 2025—Speakers in a session at the ADLM meeting in July walked attendees through their real-life cases and quandaries that called for troubleshooting skill and left their laboratories with lessons learned from each. Offering up what they called lab adventures were Joe M. El-Khoury, PhD, DABCC, professor of laboratory medicine at Yale School of Medicine; Christopher Farnsworth, PhD, DABCC, associate professor of pathology and immunology at Washington University School of Medicine in St. Louis; and Reid Rosehill, MS, MLS(ASCP), laboratory manager at the University of California San Francisco.
June 2025—With few FDA-cleared or -approved methods for tumor marker testing in body fluids, it is the laboratory that’s responsible for the tests. “A specimen arrives at your door, and you have to figure out what, if anything, you’re going to do,” said Jonathan Genzen, MD, PhD, MBA.
June 2025—Patients who present to the ED with an elevated cardiac troponin above the 99th percentile and suspected acute coronary syndrome but in whom myocardial infarction is not diagnosed are at risk for future cardiac events. But how much risk? Last fall, the Food and Drug Administration cleared Siemens Healthineers’ Atellica IM High-Sensitivity Troponin I assay for prognostic risk stratification, an expanded intended use claim. Now, with this newly cleared use, “novel information is created from traditional indications,” said Christopher deFilippi, MD, who was recently director of the Biocore research laboratory and vice chair of academic affairs, Inova Schar Heart and Vascular in Fairfax, Va., and is now, since June 1, at the University of Maryland.
